Chemistry:6-MBPB
6-MBPB, also known as 6-(2-methylaminobutyl)benzofuran (6-MABB), is a monoamine releasing agent (MRA) and entactogen-like drug of the amphetamine, phenylisobutylamine, and benzofuran families.[1][2][3][4][5] It is a positional isomer of 5-MBPB (5-MABB).[1][2][3][4][5]
The drug appears to act as a serotonin–norepinephrine–dopamine releasing agent (SNDRA).[1][2] The EC50 values for induction of monoamine release in rat brain synaptosomes have been reported for the individual enantiomers of 6-MBPB.[2] In the case of (S)-6-MBPB, they were 54 nM for serotonin, 77 nM for norepinephrine, and 41 nM for dopamine, whereas for (R)-6-MBPB, they were 172 nM for serotonin, 227 nM for norepinephrine, and inactive for dopamine.[2] Hence, (S)-6-MBPB is an SNDRA, whereas (R)-MBPB is a serotonin–norepinephrine releasing agent (SNRA).[2] The enantiomers showed a mixed profile of acting as full versus partial releasers.[2] Unlike 5-MAPB, it is a relatively weak serotonin 5-HT1B receptor agonist.[6] 6-MBPB partially substituted for MDMA in animal drug discrimination tests at lower doses and fully substituted for MDMA at the highest dose, suggesting that it has entactogen-like effects.[1][2][4]
Along with 5-MBPB, 6-MBPB was patented by Matthew Baggott and Tactogen in 2021.[5] It was first described in the scientific literature by 2022.[3][4] 6-MBPB, along with other drugs like 5-MBPB, is being investigated as a novel MDMA-like drug for potential therapeutic purposes in medicine.[1][2]
See also
- Substituted benzofuran
- 5-MBPB (5-MABB)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "A "Furious" Effort to Develop Novel 3,4-Methylenedioxymethamphetamine-Like Therapeutics". J Pharmacol Exp Ther 391 (1): 18–21. September 2024. doi:10.1124/jpet.124.002183. PMID 39293859.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine". J Pharmacol Exp Ther 391 (1): 22–29. September 2024. doi:10.1124/jpet.123.001837. PMID 38272669.
- ↑ 3.0 3.1 3.2 Benzofuran Derivatives Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine (MDMA) in Male Sprague-Dawley Rats. 10 November 2022. https://scholarworks.wmich.edu/masters_theses/5343/. Retrieved 21 January 2025.
- ↑ 4.0 4.1 4.2 4.3 "Poster 28: Benzofuran derivatives substitute for the discriminative stimulus effects of MDMA in male Sprague-Dawley rats". 14th Annual Behavior, Biology, and Chemistry [(BBC]): Translational Research in Addiction, San Antonio Texas, Embassy Landmark, 26-27 February 2022. February 2022. p. 20. https://ww2.uthscsa.edu/artt/print/BBCProgram2022.pdf#page=20. "Stimulus substitution tests were conducted with (RS) 5-MAPB, (R)-5-MAPB, (S)-5-MAPB, (R)-5-MBPB, (S)-5-MBPB, (R)-6-MBPB, and (S)-6-MBPB. All substances produced full substitution for MDMA. In separate experiments, serotonin release and reuptake assays with rat synaptosomes indicated these substances are substrate releasers of serotonin with nanomolar potency; slightly higher potency was observed with the S-enantiomers. The benzofuran scaffold may allow development of substances that retain MDMA-like therapeutic effects while reducing toxicities associated with MDMA."
- ↑ 5.0 5.1 5.2 "Advantageous benzofuran compositions for mental disorders or enhancement". 8 June 2021. https://patents.google.com/patent/WO2021252538A2/en.
- ↑ Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", US patent 20230150963, published 2023 May 18, assigned to Tactogen
External links
 |  |
